LP
CYTK icon

LMR Partners’s Cytokinetics CYTK Stock Holding History

LMR Partners’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.95M Buy
34,653
+30,353
+706% +$2.18M 0.01% 795
2026
Q1 		$283K Buy
+4,300
New +$273K ﹤0.01% 1153
2025
Q2 		– Sell
-20,000
Closed -$804K – 1433
2025
Q1 		$804K Sell
20,000
-83,346
-81% -$3.83M 0.01% 827
2024
Q4 		$4.86M Sell
103,346
-71,429
-41% -$3.71M 0.04% 396
2024
Q3 		$9.23M Buy
+174,775
New +$9.74M 0.07% 228
2017
Q2 		– Sell
-12,118
Closed -$156K – 617
2017
Q1 		$156K Buy
+12,118
New +$142K 0.02% 337

Other funds holding CYTK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

LMR Partners's CYTK Position: Q2 2026 in Review

LMR Partners increased its Cytokinetics (CYTK) stake by 706% in Q2 2026, buying an estimated $2.18M and bringing the position to 34,653 shares worth $2.95M. The position accounts for 0.01% of the portfolio, ranked #795.

LMR Partners first reported a position in CYTK in Q1 2017 and has held it in 6 quarters since. The position peaked at $9.23M in Q3 2024. 483 funds tracked by Wall St. Rank hold CYTK as of Q2 2026.

  • LMR Partners held 34,653 shares of Cytokinetics worth $2.95M as of Q2 2026.
  • LMR Partners bought 30,353 Cytokinetics shares in Q2 2026, an estimated $2.18M.
  • Cytokinetics made up 0.01% of LMR Partners's portfolio in Q2 2026, its #795 holding.
  • LMR Partners first reported a position in Cytokinetics in Q1 2017 and has held it in 6 quarters since.
  • LMR Partners's Cytokinetics position peaked at $9.23M in Q3 2024.
  • 483 funds tracked by Wall St. Rank held Cytokinetics as of Q2 2026.

Based on LMR Partners's 13F filing for Q2 2026, filed 14 Aug 2026.